Comparison of Immature Platelet Fraction (IPF) and Procalcitonin (PCT) as Biomarkers of Infection Severity in Relation to NS1 Antigen in Patients with Dengue Hemorrhagic Fever (DHF)
DOI:
https://doi.org/10.55175/cdk.v53i06.2035Keywords:
Dengue hemorrhagic fever (DHF), immature platelet fraction (IPF), NS1, procalcitonin (PCT), thrombocytopeniaAbstract
Background: Dengue hemorrhagic fever (DHF) is an infectious disease caused by the dengue virus (DENV) and transmitted by the Aedes aegypti and Aedes albopictus mosquito vectors. This disease remains a major global health problem, particularly in tropical regions such as Indonesia. Clinical indicators of DHF severity include thrombocytopenia and shock, which are associated with high viremia levels and an increase in dengue NS1 antigen in the vascular system. This study compares immature platelet fraction (IPF) and procalcitonin (PCT) levels as biomarkers of infection severity in relation to DENV NS1 antigen positivity. Methods: This study included 35 patients with DHF and 35 healthy controls. IPF values and PCT levels were measured. Differences between the two groups were analyzed using an independent t-test. Results: p-values for both IPF and PCT were < 0.05, indicating statistically significant differences between DHF patients and healthy controls. These findings suggest that higher IPF values are associated with thrombocytopenia, whereas elevated PCT levels may reflect more severe infection, including dengue shock syndrome. Conclusion: There are significant differences in IPF and PCT levels between DHF patients and controls, depending on dengue NS1 antigen positivity. IPF may serve as an indicator of thrombocytopenia, while PCT may be a marker of infection severity, including dengue shock syndrome, in patients with dengue hemorrhagic fever.
Downloads
References
World Health Organization (WHO). Global strategy for dengue prevention and control 2012–2020 [Internet]. Geneva: World Health Organization; 2012 [cited 2026 May 28]. Available from: https://iris.who.int/handle/10665/75303.
Kementerian Kesehatan. Waspada DBD di musim kemarau [Internet]. 2024. Available from: https://kemkes.go.id/id/waspada-dbd-di-musim-kemarau.
Geiss BJ, Stahla H, Hannah AM, Gari AM, Keenan SM. Focus on flaviviruses: current and future drug targets. Future Med Chem. 2009 May;1(2):327–44. doi: 10.4155/fmc.09.27.
Weaver SC, Vasilakis N. Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Infect Genet Evol. 2009 Jul;9(4):523–40. doi: 10.1016/j.meegid.2009.02.003.
Chen HR, Lai YC, Yeh TM. Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate. J Biomed Sci. 2018 Dec 24;25(1):58. doi: 10.1186/s12929-018-0462-0.
Patro ARK, Mohanty S, Prusty BK, Singh DK, Gaikwad S, Saswat T, et al. Cytokine signature associated with disease severity in Dengue. Viruses. 2019 Jan 8;11(1):34. doi: 10.3390/v11010034.
MacQueen BC, Christensen RD, Henry E, Romrell AM, Pysher TJ, Bennett ST, et al. The immature platelet fraction: creating neonatal reference intervals and using these to categorize neonatal thrombocytopenias. Journal of Perinatology. 2017 Jul 6;37(7):834–8. doi: 10.1038/jp.2017.48.
Thanachartwet V, Desakorn V, Sahassananda D. Serum procalcitonin and peripheral venous lactate for predicting dengue shock and/or organ failure: a prospective observational study. Vol. 83. 2016;83:1–19. doi: 10.1371/journal.pntd.0004961.
Zainah S, Wahab AHA, Mariam M, Fauziah MK, Khairul AH, Roslina I, et al. Performance of a commercial rapid dengue NS1 antigen immunochromatography test with reference to dengue NS1 antigen-capture ELISA. J Virol Methods. 2009 Feb;155(2):157–60. doi:10.1016/j.jviromet.2008.10.016.
Sysmex Corporation. XN-series white paper: fluorescence flow cytometry for hematology testing [technical brief]. Kobe: Sysmex Corporation;2022.
Biotime Biotechnology Co., Ltd. Product manual: Biotime rapid quantitative test series. Xiamen: Biotime Biotechnology Co., Ltd.; 2022.
Kularatne SA, Dalugama C. Dengue infection: Global importance, immunopathology and management. Clin Med (Lond). 2022 Jan;22(1):9–13. doi: 10.7861/clinmed.2021-0791.
de la Cruz-Hernandez SI, Flores-Aguilar H, Gonzalez-Mateos S, Lopez-Martinez I, Alpuche-Aranda C, Ludert JE, et al. Determination of viremia and concentration of circulating nonstructural protein 1 in patients infected with dengue virus in Mexico. Am J Trop Med Hyg. 2013 Mar;88(3):446–54. doi: 10.4269/ajtmh.12-0023.
Lee PX, Ting DHR, Boey CPH, Tan ETX, Chia JZH, Idris F, et al. Relative contribution of nonstructural protein 1 in dengue pathogenesis. Journal of Experimental Medicine. 2020 Sep 7;217(9):e20191548. doi: 10.1084/jem.20191548.
Bhatt P, Sabeena SP, Varma M, Arunkumar G. Current understanding of the pathogenesis of dengue virus infection. Curr Microbiol. 2021;78(1):17–32. doi: 10.1007/s00284-020-02284-w.
Abeysuriya V, Seneviratne SL, de Mel P, Clarice CSH, de Mel C, Chandrasena L, et al. The immature platelet fraction, a predictive tool for early recovery from dengue-related thrombocytopenia: a prospective study. Trans R Soc Trop Med Hyg. 2022 May;116(5):424—32. doi: 10.1093/trstmh/trab135.
Klinger MHF, Jelkmann W. Review: role of blood platelets in infection and inflammation. Journal of Interferon & Cytokine Research. 2002 Sep;22(9):913–22. doi: 10.1089/10799900260286623.
Mathew A, West K, Kalayanarooj S, Gibbons R V, Srikiatkhachorn A, Green S, et al. B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis. 2011;204(10):1514–22. doi: 10.1093/infdis/jir607.
Barczak S, Hertz Z, Badura B. The role of serum procalcitonin as a diagnostic marker in patients with dengue: a review. Prospects in Pharmaceutical Sciences. 2025 Apr 24;23(2):19–23. doi: 10.56782/pps.284.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ichwan Baihaki, Mutmainnah, Heru Purwanto Nugroho
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
